Supriya Lifescience Seeks Shareholder Approval for Mr. Balasaheb Sawant's Re-appointment
Supriya Lifescience is seeking shareholder approval to re-appoint Mr. Balasaheb Sawant as Whole Time Director for a three-year term from May 26, 2026, to May 25, 2029. The voting will take place via postal ballot and e-voting from July 23 to August 21, 2026. Mr. Sawant's remuneration is proposed at ₹8.78 lakh per month.
The re-appointment of a key managerial personnel is a standard governance practice and is unlikely to have a significant immediate impact on the company's stock price or operations.
The announcement is a routine corporate action regarding the re-appointment of a director, which is a standard governance process. It does not contain any immediately positive or negative financial or operational news.
Supriya Lifescience Limited has issued a notice of postal ballot seeking shareholder approval for the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Key Managerial Personnel. The proposed term for his re-appointment is for three consecutive years, commencing from May 26, 2026, and concluding on May 25, 2029.
The company is facilitating this approval process through remote e-voting, with the voting period commencing on Thursday, July 23, 2026, at 9:00 a.m. IST and concluding on Friday, August 21, 2026, at 5:00 p.m. IST. The results of the postal ballot are scheduled to be declared on or before Saturday, August 22, 2026. Mr. Sawant, who has over 29 years of experience in API Production Planning and Material Management, has been associated with the company since February 24, 2017. His remuneration is proposed to be a maximum of ₹8,78,080 per month, inclusive of basic salary, HRA, perquisites, allowances, bonus, and performance incentives, subject to applicable laws and approvals.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.